Centre National De La Recherche Scientifique

Universitè De Montpellier

Centre Hospitalier Universitaire De Montpellier

Centre Hospitalier Et Universitaire De Montpellier

Alboukadel Kassambara

Jérôme Moreaux

Wafa Hassen

Disclosed is a method for in vitro predicting the outcome of an individual having a multiple myeloma, including: —a) measuring the expression level of at least 2 genes encoding a ROS detoxifying (AOX) protein selected in a group including AKR1 B1, ARNT, CAT, CBR1, DHCR24, EGLN1, GLRX2, HIF1A, MGST1, MSRB1, PRDX6, SLC7A11, SOD1, SRXN1, TALDO1 and TXN and/or the expression level of at least 2 genes encoding ROS producing (ROS) protein selected in a group including CYBA, CYB5A, CYC1, NCF1B, NCF1C, NCF4, NDUFA12, NDUFS2, NDUFS8, SHC1 and UQCR10, in a biological sample obtained from the individual; —b) calculating an AOX score value and/or a ROS score value from the respective expression level(s) obtained at step a); —c) classifying the individual as having a good prognosis status or a bad prognosis status, by comparing the score value obtained at step b) with a reference score value.

Growing community of inventors

Marvejols, France

Alboukadel Kassambara